We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Patients with heart failure and reduced ejection fraction after sacubitril/valsartan treatment may be at risk for major adverse cardiovascular events according to ΔRDW.
- Authors
Sutar, Shashi Bhusan; Naik, Jitendra; Oram, Gouri; Behera, Desabandhu
- Abstract
The objective of this study was to assess the correlation between alterations in the distribution width of red blood cells (RDW) and the incidence of major adverse cardiovascular events (MACEs) in patients with heart failure with reduced ejection fraction (HFRF) receiving sacubitril/valsartan therapy. Implementing Methods: After obtaining permission from the Institutional Ethics Committee, the present study was initiated. This study retrospectively examined the medical records of hospitalized patients diagnosed with HFRF. The patients were allocated into two distinct groups, namely, the traditional group and the sacubitril/valsartan group, based on whether sacubitril/valsartan was incorporated into their individual pharmacological treatment regimen. The RDW values before and after treatment with sacubitril/valsartan are documented as RDW1 and RDW2, respectively. ΔRDW is defined as the value obtained by subtracting RDW1 from RDW2. Based on ΔRDW >0 or ≤0, patients in the sacubitril/valsartan group were categorized into two subgroups. MACEs, including mortality and readmission for myocardial infarction, acute myocardial infarction, and ischemic stroke, were documented in each cohort throughout the one-year follow-up period. Findings: Patients who received sacubitril/valsartan exhibited a reduced incidence of MACE compared to those who received conventional therapy (log-rank, P<0.001). During the follow-up period, the incidence of cardiac events was significantly higher in the ΔRDW >0 group than in the ΔRDW ≤ 0 group (Breslow, P<0.001). There was a significant positive correlation between increased RDW and a decreased likelihood of developing MACE (odds ratio [OR] = 3.044, 95% confidence interval [CI]:1.592-4.357). Furthermore, for every unit increase in RDW, the risk of developing MACE increased by 23.2% (OR=2.332, 95% CI:1.185-2.499). Treatment with sacubitril/valsartan effectively reduced the incidence of MACEs in HFRF patients. In addition, variations in RDW serve as predictors of MACEs after sacubitril/valsartan treatment.
- Subjects
MAJOR adverse cardiovascular events; ENTRESTO; HEART failure patients; VALSARTAN; VENTRICULAR ejection fraction
- Publication
Journal of Cardiovascular Disease Research (Journal of Cardiovascular Disease Research), 2024, Vol 15, Issue 3, p602
- ISSN
0975-3583
- Publication type
Article